Could This Stock Be the Next Biotech Buyout?
ALPNAlpine Immune Sciences(ALPN) The Motley Fool·2024-04-13 17:29

Vertex Pharmaceuticals' 4.9billionpurchaseofAlpineImmuneSciencesprobablywon′tbethelastacquisitionofacompanyfocusedonkidneydisease.ThebiotechnologyindustryisgettingmoreattentionthanusualfollowingabuyoutofferforAlpineImmuneSciences(ALPN−0.054.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (ALPN -0.05%) from Vertex Pharmaceuticals (VRTX -0.92%). Vertex recently offered Alpine Immune Sciences 65 per share, or about 4.9billionincash.OnApril9,thedaybeforetheannouncement,Alpine′sstockpriceclosedatabout4.9 billion in cash. On April 9, the day before the announcement, Alpine's stock price closed at about 39 per share ...